Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

51 recalls, newest first

Class III · Low risk

Levetiracetam Tablets USP

Labeling; Wrong Barcode; error in the machine-readable barcode which could result in some units being read as Naproxen Tablets 500 mg. Product is labeled correctly as Levetiracetam

Terminated Labeling / mix-up McKesson Corporation dba McKesson Drug Company NDC 63739-795-10 D-0630-2021
Class I · High risk

1% Lidocaine HCl Injection

Labeling: Label Mix-Up: some vials labeled to contain 0.5% Bupivacaine Hydrochloride Injection, USP may contain 1% Lidocaine HCl Injection, USP and some vials labeled to contain 1% Lidocaine HCl Injection, USP may contain 0.5% Bupivacaine Hydrochloride Injection, USP

Terminated Labeling / mix-up Pfizer, INC NDC 0409-4279-16 D-0627-2021
Class I · High risk

0.5% Bupivacaine Hydrochloride Injection

Labeling: Label Mix-Up: some vials labeled to contain 0.5% Bupivacaine Hydrochloride Injection, USP may contain 1% Lidocaine HCl Injection, USP and some vials labeled to contain 1% Lidocaine HCl Injection, USP may contain 0.5% Bupivacaine Hydrochloride Injection, USP

Terminated Labeling / mix-up Pfizer, INC NDC 0409-1162-19 D-0626-2021
Class III · Low risk

Thiamine HCl Injection

Labeling: Incorrect or Missing Lot and/or Exp Date: Cartons with the correct lot number 200906 contain vials labeled with the incorrect lot number 200901.

Terminated Labeling / mix-up Mylan Institutional LLC D-0601-2021
Class III · Low risk

Acyclovir Tablets

Labeling: Incorrect or Missing Lot and/or Exp Date

Terminated Labeling / mix-up Heritage Pharmaceuticals Inc NDC 23155-227-01 D-0367-2021
Class II · Moderate risk

ChloraPrep With Tint 2% w/v chlorhexidine gluconate

CGMP Deviations: Product is being recalled because at labeled storage conditions of 30*C/75% Relative Humidity, there is the potential for growth of Aspergillus penicillioides, a type of fungus, resulting in a breach of the package integrity.

Terminated Labeling / mix-up CareFusion 213, LLC D-0350-2021
Class II · Moderate risk

ChloraPrep One-Step 2% w/v chlorhexidine gluconate

CGMP Deviations: Product is being recalled because at labeled storage conditions of 30*C/75% Relative Humidity, there is the potential for growth of Aspergillus penicillioides, a type of fungus, resulting in a breach of the package integrity.

Terminated Labeling / mix-up CareFusion 213, LLC D-0349-2021
Class III · Low risk

Distributed by: DocRx

Labeling: Illegible label: Manufacturer received complaint of mis-alignment print of the printed dosing instructions on the blister card.

Ongoing Labeling / mix-up Asclemed USA Inc. dba Enovachem Pharmaceuticals D-0330-2021
Class I · High risk

heal the world

Labeling Not Elsewhere Classified: Hand sanitizer packaged in containers resembling drinking water bottles.

Terminated Labeling / mix-up Pnhc, LLC. D-0365-2021
Class I · High risk

Acetaminophen

Labeling: Label Mix-up; The bottle of over-the-counter Acetaminophen 500mg Extra Strength, 100 count, included in Health Essential Kits, labeled incorrectly with a prescription drug label instead of an OTC drug label.

Terminated Labeling / mix-up A-S Medication Solutions LLC. D-0358-2021
Class III · Low risk

Methylprednisolone Tablets USP

Labeling: Illegible label: Customer complaint received of mis-alignment print of the printed dosing instructions on the blister card.

Terminated Labeling / mix-up Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-001-03 D-0298-2021
Class I · High risk

Enoxaparin Sodium Injection

Labeling; Label Mixup; syringe barrels may contain markings for 100 mg/mL (corresponding to 100 mg/mL strength) instead of 150 mg/mL (corresponding to 120 mg/0.8mL strength)

Ongoing Labeling / mix-up Apotex Corp. NDC 60505-0796-4 D-0262-2021
Class I · High risk

Enoxaparin Sodium Injection

Labeling; Label Mixup; syringe barrels may containing markings for 150 mg/mL (corresponding to 120 mg/0.8mL strength) instead of 100 mg/mL markings (corresponding to 100 mg/mL strength)

Ongoing Labeling / mix-up Apotex Corp. NDC 60505-0795-4 D-0261-2021
Class III · Low risk

Glycopyrrolate Injection

Labeling; Label Mix-up; correctly labeled 2 mL vials were packaged into blister strips labeled for 1 mL vials

Terminated Labeling / mix-up Accord Healthcare, Inc. NDC 16729-472-08 D-0250-2021
Class II · Moderate risk

Spironolactone Tablets

Labeling: Label Mix-Up - Prepackaged bottles labeled spironolactone 50 mg may contain spironolactone 25 mg tablets.

Ongoing Labeling / mix-up Bryant Ranch Prepack, Inc. dba BRP Pharmaceuticals NDC 63629-1067-01 D-0304-2021
Class I · High risk

Spironolactone Tablets

Labeling: Label Mix-Up - Prepackaged bottles labeled spironolactone 25 mg may contain spironolactone 50 mg tablets.

Ongoing Labeling / mix-up Bryant Ranch Prepack, Inc. dba BRP Pharmaceuticals NDC 63629-1064-01 D-0303-2021
Class I · High risk

Cisatracurium Besylate Injection

Labeling: Label mix-up: Carton of Cisatracurium Besylate Injection, USP was observed to contain ten vials mislabeled as Phenylephrine Hydrochloride Injection, USP, but confirmed to contain Cisatracurium

Terminated Labeling / mix-up Meitheal Pharmaceuticals Inc NDC 71288-712-05 D-0286-2021
Class I · High risk

Benzonatate capsules

Labeling: Label Mix-up: Bottle labeled as Benzonatate 100 mg capsules contained Benzphetamine 50 mg tablets and a bottle labeled as Benzphetamine 50 mg tablets contained Benzonatate 100 mg capsules.

Terminated Labeling / mix-up Calvin Scott & Company, Inc. NDC 67877-0573-05 D-1124-2022
Class III · Low risk

Benzphetamine tablets

Labeling: Label Mix-up: Bottle labeled as Benzonatate 100 mg capsules contained Benzphetamine 50 mg tablets and a bottle labeled as Benzphetamine 50 mg tablets contained Benzonatate 100 mg capsules.

Terminated Labeling / mix-up Calvin Scott & Company, Inc. NDC 10702-0040-50 D-1123-2022

Recalls by year